Recombinant Human DSG3 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-02258P-100UG

Human DSG3 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human DSG3 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-02258P-100UG
Collections: High-quality recombinant proteins, Other recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human DSG3 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Glu50-Arg615. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | P32926 |
Target Symbol | DSG3 |
Synonyms | Desmoglein-3; PVA; CDHF6; SG3; DSG3 |
Species | Human |
Expression System | HEK293 |
Tag | C-His |
Expression Range | Glu50-Arg615 |
Mol. Weight | The protein has a predicted MW of 64 kDa. Due to glycosylation, the protein migrates to 70-75 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Human DSG3, His Tag at 0.5ug/ml (100ul/Well) on the plate. Dose response curve for Anti-DSG3 Antibody, hFc Tag with the EC50 4.5ng/ml determined by ELISA. Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | To identify genes that could potentially serve as molecular therapeutic markers for human head and neck cancer (HNC),DSG3 is identified overexpressed in HNC, with the degree of overexpression associated with clinicopathologic features of the tumor. Inhibition of DSG3 significantly suppresses carcinogenic potential in cellular and in vivo animal studies. DSG3 is a potential molecular target in the development of adjuvant therapy for HNC. |